Clinical trials: Pharmacogenetic Testing
- Condition Pharmacogenetic Testing
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
This study is conducted globally. This study describes pharmacogenetic testing of saliva samples from patients who participated in the NN1731-3562 trial (adept™2) (NCT01392547).
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- NCT02541942
- Testing
- No treatment given
- Where
- 15 sites in United States, Greece and 5 more
- Volunteers
- 19 people
- Sponsor
- Novo Nordisk A/S